ARTHEx Biotech Announces Appointment of Glenn P. Sblendorio as Chairman of the Board
Why now
Thesis: Private biotech board change, no tradable impact
Catalyst to watch: Future trial or financing announcement
Main risk: Private company, no public disclosure duties
Why it matters
Board appointment at a private clinical-stage biotech; no listed security impact.
Details
-Experienced biopharmaceutical executive brings decades of leadership in corporate strategy, finance and business development to support ARTHEx's next phase of growth- VALENCIA, Spain, Sept. 29, 2026 /PRNewswire/ -- Arthex Biotech, a clinical-stage biotechnology company advancing...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-29 07:00 UTC